|Positive WB detected in||human placenta tissue, human plasma tissue, Jurkat cells|
|Positive IHC detected in||human tonsillitis tissue, human renal cell carcinoma tissue, human breast cancer tissue, human lymphoma tissue, human liver tissue|
Note: suggested antigen retrieval with TE buffer pH 9.0; (*) Alternatively, antigen retrieval may be performed with citrate buffer pH 6.0
|Western Blot (WB)||WB : 1:500-1:1000|
|Immunohistochemistry (IHC)||IHC : 1:50-1:500|
|Sample-dependent, check data in validation data gallery|
10927-1-AP targets CXCL13/BCA1 in WB, IHC, IF, ELISA applications and shows reactivity with human samples.
|Host / Isotype||Rabbit / IgG|
|Immunogen||CXCL13/BCA1 fusion protein Ag1358|
|Full Name||chemokine (C-X-C motif) ligand 13|
|Calculated molecular weight||13 kDa|
|Observed molecular weight||10 kDa|
|GenBank accession number||BC012589|
|Gene ID (NCBI)||10563|
|Purification Method||Antigen affinity purification|
|Storage Buffer||PBS with 0.02% sodium azide and 50% glycerol pH 7.3.|
|Storage Conditions||Store at -20°C. Stable for one year after shipment. Aliquoting is unnecessary for -20oC storage.|
BLR1 (Burkitt lymphoma receptor-1), also called CXCR5, is highly expressed on Burkitt lymphoma cells and B lymphocytes. It may therefore function in the homing of B lymphocytes to follicles. It was reported that the B cell chemokine CXCL13 is elevated in MS serum and cerebrospinal fluid. CXCL13 is also regarded as a proposed serum biomarker of synovitis in RA( Rheumatoid arthritis). CXCL13 consists of a 22-aa signal peptide and a 87-aa mature poly-peptide.
The role of high serum CXCL13 level in Waldenström macroglobulinemia.
Defined lifestyle and germline factors predispose Asian populations to gastric cancer.
Aging (Albany NY)
Immune profiling reveals prognostic genes in high-grade serous ovarian cancer.
J Matern Fetal Neonatal Med
A role for CXCL13 (BCA-1) in pregnancy and intra-amniotic infection/inflammation.
Mol Med Rep
MicroRNA‑186‑5p mediates osteoblastic differentiation and cell viability by targeting CXCL13 in non‑traumatic osteonecrosis.
Identification of CXCL13 as a potential biomarker in clear cell renal cell carcinoma via comprehensive bioinformatics analysis.